alpharma news from FierceBiotech
NewsAlpharma shares skyrocket on King's buyout offer
King Pharmaceuticals will try and join the billion-dollar buyout club with a $1.38 billion cash offer for Alpharma. King is offering $33 a share, a 37 percent premium on Thursday's close and a 49 Read more...
Purdue jumps ahead in pain drug race
With three significant development programs at work on a tamper-free alternative to the blockbuster OxyContin franchise, Purdue Pharma is bracing for an upcoming FDA panel review of its new pain Read more...
Alpharma withdraws painkiller NDA
Alpharma has withdrawn its NDA for Embeda, its extended-release painkiller. While the company's drug qualified for priority review, Alpharma said that "certain technical issues around data Read more...
ALSO NOTED: Dynogen goes public; Alpharma sells ingredients unit for $395M; Arizona launches new venture fund; and much more...
> Dynogen Pharmaceuticals is going public in a buyout deal with Apex Bioventures Acquisition Corp. Dynogen shareholders will initially receive $98 million in the deal, with Dynogen merging with a Read more...
Alpharma touts Phase III pain drug data
Alpharma today announced positive results from its Phase III trial for its extended-release opioid, ALO-01. The drug demonstrated significant pain relief, which was the primary endpoint of the trial. Read more...
Alpharma sub inks $202M deal for pain drug
A subsidiary of Alpharma has agreed to pay Germany's IDEA up to $202 million in upfront fees and milestones for the U.S. rights to the late-stage pain drug Diractin (ketoprofen in Transfersome gel), Read more...
SPOTLIGHT: Alpharma licenses rights to NSAID patch
in deal with Institut BiochimiqueAlpharma has struck a deal with Institut Biochimique for the exclusive license and distribution rights to market the Flector Patch, the first Read more...
C&L: Frost resigns at ImClone
ImClone Systems' chief scientific officer Philip Frost has resigned. Astex Therapeutics has hired John Aston as CFO and a member of its board of directors. John Fess has been named CEO of Blue Heron Biotechnology. Fess succeeds John Mulligan, Ph.D., Blue Heron's founder who will … Read more...C&L: Morhet chosen to run InNexus
InNexus Biotechnology has named Jeff Morhet as its new CEO and president. He succeeds Dr. Charles Morgan, who co-founded the company. DOR BioPharma has appointed Christopher J. Schaber, Ph.D., as its new president and CEO to replace Michael T. Sember. Synthetech has appointed … Read more... | Press ReleasesAlpharma Withdraws Application for Painkiller Alpharma Withdraws Application for Painkiller 4/22/2008 BRIDGEWATER, NJ -- Apr 21, 2008 -- Alpharma, a global specialty pharmaceutical company, today announced that it has withdrawn its New Drug Read more... PRESS RELEASE: Alpharma Says Late-Stage Trial of Pain Reliever Meets Goal Alpharma Says Late-Stage Trial of Pain Reliever Meets Goal BRIDGEWATER, NJ -- Nov 29, 2007 -- Alpharma, a leading, global specialty pharmaceutical company, today announced positive results from its Read more... PRESS RELEASE: IDEA Signs Major Licensing Agreement with Alpharma; Alpharma to Pay $60 Million Upfront IDEA Signs Major Licensing Agreement with Alpharma; Alpharma to Pay $60 Million Upfront LONDON, NEW YORK and HAMILTON, BERMUDA: September 6, 2007 - Celtic Pharmaceutical Holdings L.P. ("Celtic Read more... |
Get more alpharma coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets